Navigation Links
'Seena' clinical trials named for pancreatic cancer advocate
Date:12/1/2011

PHOENIX, Ariz. -- A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.

The 'Seena I' clinical trial is named for Seena Magowitz, a cancer research advocate and patient who fell victim to pancreatic cancer the nation's fourth leading cause of cancer death.

Pancreatic cancer patients can soon enroll in Seena I, which is planned for at least four clinical sites across the nation, including Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare.

The Pancreatic Cancer Research Team (PCRT) will supervise the Seena trials. PCRT is a worldwide consortium of 45 clinical institutions led by TGen and dedicated to finding a cure for pancreatic cancer.

For nearly a decade, Scottsdale resident Roger Magowitz has championed research into finding a cure for pancreatic cancer, a disease that took the life of his mother, Seena, in 2001.

"I am deeply honored and filled with tremendous hope that the clinical trials named for my mother, Seena, will lead perhaps within just a few years to an actual cure for pancreatic cancer," said Roger Magowitz, President of the Seena Magowitz Foundation, who has donated $1 million to the TGen pancreatic cancer initiative.

The pancreas is a gland behind the stomach that secretes enzymes into the upper part of the small intestine to help digestion. It also produces hormones, including insulin, which helps regulate the metabolism of sugars.

The Seena I trial consists of three treatment components:

  • The first treatment will be with gemcitabine and nab-paclitaxel (Abraxane) for a maximum of 6 months.
  • The next treatment is with a combination of four drugs: 5-FU (fluoruracil); Leucovorin; Oxaliplatin; and Irinotecan. This combination is called FOLFIRINOX, an acronym of
    '/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Vaccine targeting latent TB enters clinical testing
2. Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy
3. BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS
4. Heart rate recovery predicts clinical worsening in pulmonary hypertension
5. Worlds first stem cell bandage in human clinical trials
6. Combination therapy shows potent tumor growth inhibition in preclinical studies
7. CBIs Interactive Response Technologies for Clinical Trials - the Only IVR/IWR Event of Its Kind - Will Be in Philadelphia on November 14-15, 2011
8. Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use
9. Professor Peter J. Coffeys stem cell therapy for Age-Related Macular Degeneration expected to begin clinical trials in 2012
10. AMIA advises FDA on clinical decision support
11. Reports highlight the evolving role of clinical microbiology laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... Scientists at the Salk Institute for Biological Studies ... plants to adapt to various environments, but could also benefit ... March 6 in Nature , the findings show that ... world, their epigenomic makeup is as varied as the environments ...
... (CUMC) researchers have found the first evidence that selective ... hippocampus, can reduce anxiety without affecting learning. The findings ... be used to treat certain anxiety disorders, such as ... cognitive side effects. The study, conducted in mice, was ...
... MA "Use it or lose it." The saying ... to protecting against Alzheimer,s disease. Previous studies have shown ... may help delay the onset of dementia in Alzheimer,s ... Dennis Selkoe, MD, co-director of the Center for Neurologic ...
Cached Biology News:Hidden layer of genome unveils how plants may adapt to environments throughout the world 2Hidden layer of genome unveils how plants may adapt to environments throughout the world 3Portion of hippocampus found to play role in modulating anxiety 2Portion of hippocampus found to play role in modulating anxiety 3Use it or lose it 2
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and oligonucleotide ... capability to serve biotechnology pharmaceutical clients. A commitment ... to drive Nitto Avecia to enhance synthesis scale ... , In Fall 2014, Nitto Avecia first demonstrated ... Milford, MA facility, which is recognized as a ...
(Date:4/30/2015)... 30, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... of biosimilar therapeutics including high value and difficult ... its previously announced underwritten public offering of 6,750,000 ... offering price of $15.50 per share. This includes ... their option to purchase up to 750,000 additional ...
(Date:4/30/2015)... 2015 Available in select spas ... , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream ... while battling the weakening threat of inflammaging, aging ... formulated with star ingredient GLYCOSEA, a complex of ... complex of soothing minerals and trace elements. GLYCOSEA ...
(Date:4/29/2015)... April 29, 2015 SPIE DSS, ... imaging on the East Coast, reaffirmed its value last ... applications developers, and industry suppliers to meet and advance ... multiple applications. , The event included 55 conferences in ... scientific sensing and imaging -- and an exhibition showcasing ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... 2011 Amgen (Nasdaq: AMGN ) and ... develop XmAb ® 5871, an Fc- engineered monoclonal antibody ... late-stage preclinical development for the treatment of autoimmune diseases. ... Amgen has the option to an exclusive worldwide license ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... Board of Directors: Kevin L. Eastwood has ... Appleman, Ph.D. has been promoted to Senior Vice President, Research ... Senior Vice President, Drug Development and Chief Medical Officer, has ...
... France and CAMBRIDGE, Mass., Jan. 6, 2011 GENFIT ... forefront of drug discovery and development, focusing on the ... disorders, today announced its presence at two U.S. events: ... to 14th, 2011) and the Biotech Showcase (from January ...
Cached Biology Technology:Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 2Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 3Anadys Pharmaceuticals Augments Management Team and Board of Directors 2Anadys Pharmaceuticals Augments Management Team and Board of Directors 3Anadys Pharmaceuticals Augments Management Team and Board of Directors 4GENFIT: Strong U.S. Exposure for Its Biomarker Activity 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 3
... systems for cultivation of microorganisms and human ... bio-pharmaceutical products maximum performance and economy for ... cell fermentation 10 L 1,500 L. ... ,*Fully automated control system ,*High-quality components ...
... for foraging behavior.The Spatial Behavior line is a ... camera, frame grabber, and feature extraction software and ... up to 6 moving animals. Software automatically ... allows video replay of all or machine-selected events. ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
... The Rice Oligo Microarray, 22K ... of rice genes associated with biological ... abiotic stress response. Each microarray contains ... of the rice (japonica) genome focuses ...
Biology Products: